The USA-based company is powered by a propietary Clinical Discovery Engine which integrates and analyzes proprietary clinical, epidemiological and patient-derived biomolecular datasets, generated in partnership with the Vall d’Hebron Institute of Research, to establish a deeper understanding of IMID diseases.
IMIDomics has identified previously unrecognized targets, six of which have been selected for development within IMIDomics’ active drug pipeline.
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze